Drug Trial Radar · NCT06891417
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
Nov 3, 2027
Study completion Nov 3, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 44 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive). There will also be an assessment to potentially obtain an early immunogenicity signal of the Chlamydia mRNA vaccine candidate. This study will consist of 2 Cohorts assessing the safety of the two different doses: Cohort A (Dose 1 or placebo) and Cohort B (Dose 2 or placebo). All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.
Conditions
- Chlamydia Trachomatis Immunization
Interventions
Chlamydia mRNA VaccineBiological
Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular injection
PlaceboOther
Pharmaceutical Form: Solution for injection Route of Administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of immediate unsolicited systemic adverse events (AEs)Time frame: Within 30 minutes after each vaccine injection
- Presence of solicited injection site and systemic reactionsTime frame: Up to 8 days, including the day of each vaccine injection
- Presence of unsolicited AEsTime frame: Up to 28 days after each vaccine injection.
- Presence of medically attended adverse events (MAAEs)Time frame: Up to 6 months after last vaccine injection
- Presence of all serious AEs (SAEs) and all adverse events of special interest (AESIs)Time frame: Up to 12 months after last vaccine injections
- Presence of related SAEs, and fatal SAEsTime frame: Throughout the study, appriximatley 18 months
- Presence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)Time frame: Up to 8 days, including the day of each vaccine injection
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 0360002
Bruce, Australian Capital Territory, Australia · Recruiting
Investigational Site Number : 0360006
Maroubra, New South Wales, Australia · Recruiting
Investigational Site Number : 0360005
Sydney, New South Wales, Australia · Recruiting
Investigational Site Number : 0360001
Albion, Queensland, Australia · Recruiting
Investigational Site Number : 0360004
Morayfield, Queensland, Australia · Recruiting
Investigational Site Number : 0360003
Southport, Queensland, Australia · Recruiting
Investigational Site Number : 0360010
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.